Namenda Buyers Want Cert. In Pay-For-Delay Fight

Law360 (July 21, 2020, 8:33 PM EDT) -- Drug buyers who claim that a slew of pharmaceutical companies conspired to keep a generic version of the brand name Alzheimer's drug Namenda off the market are asking a New York federal court to sign off on their class action.

The end payors have asked U.S. District Judge Colleen McMahon to grant them certification so they can continue pursuing their claims against the companies that have not yet settled out. While their request was originally made earlier this month, a public version of the filing only hit the docket Monday.

"The core issues in this case — the unlawfulness of defendants'...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!